![]() | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C20H20N2O2 |
| Molar mass | 320.392 g·mol−1 |
| 3D model (JSmol) | |
| |
| (verify) | |
Befuraline (DIV-154) is a psychoactive drug and member of the piperazine chemical class which was developed in Germany in the 1970s.1 Befuraline has stimulant and antidepressant effects and has seen some use in Germany and France, although it has never become widely used.2 Befuraline's active metabolite benzylpiperazine is likely to contribute to its effects.
Synthesis

A one-step coupling between coumarilic acid (benzofuran-2-carboxylic acid) [496-41-3] (1) and benzylpiperazine (BzP) (2) gives an amide, and hence Befuraline (3).
References
References
- Boksay IJ, Popendiker K, Weber RO, Söder A (1979). "Synthesis and pharmacological activity of befuraline (N-benzo[b]furan-2-ylcarbonyl-N'-benzylpiperazine), a new antidepressant compound". Arzneimittel-Forschung. 29 (2): 193–204. PMID 582130.
- Gastpar M, Gastpar G, Gilsdorf U (November 1985). "Befuraline, its safety and efficacy in depressed inpatients". Pharmacopsychiatry. 18 (6): 351–5. doi:10.1055/s-2007-1017396. PMID 4089015. S2CID 9322026.
- DE2157424 idem Rolf-Ortwin Weber, Alfons Soder, Istvan Boksay, U.S. patent 4,374,990 (1980 to Hoechst Aktiengesellschaft).
